Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Silence Therapeutics Plc ADR (SLN)

Silence Therapeutics Plc ADR (SLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 328,749
  • Shares Outstanding, K 47,234
  • Annual Sales, $ 43,260 K
  • Annual Income, $ -45,310 K
  • EBIT $ -84 M
  • EBITDA $ -84 M
  • 60-Month Beta 1.35
  • Price/Sales 7.79
  • Price/Cash Flow N/A
  • Price/Book 1.59

Options Overview Details

View History
  • Implied Volatility 136.43% (+30.83%)
  • Historical Volatility 60.82%
  • IV Percentile 48%
  • IV Rank 11.84%
  • IV High 783.33% on 04/11/25
  • IV Low 49.52% on 09/08/25
  • Expected Move (DTE 13) 0.85 (12.21%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 32
  • Volume Avg (30-Day) 56
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 2,333
  • Open Int (30-Day) 3,544
  • Expected Range 6.11 to 7.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.37
  • Number of Estimates 3
  • High Estimate -0.06
  • Low Estimate -0.69
  • Prior Year 0.27
  • Growth Rate Est. (year over year) -237.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.80 +20.00%
on 11/07/25
7.43 -6.27%
on 12/05/25
+0.72 (+11.54%)
since 11/05/25
3-Month
4.42 +57.47%
on 09/15/25
7.78 -10.48%
on 10/23/25
+1.27 (+22.32%)
since 09/05/25
52-Week
1.97 +253.30%
on 04/10/25
8.88 -21.62%
on 12/09/24
-1.19 (-14.60%)
since 12/05/24

Most Recent Stories

More News
Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in a fireside chat at...

SLN : 6.96 (-2.38%)
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

SANRECO Phase 2 study of divesiran in polycythemia vera (PV) fully enrolled; topline results anticipated in 3Q 2026 Strong balance sheet and cash runway into 2028

SLN : 6.96 (-2.38%)
5 Under-the-Radar Biotech Stocks That Could Soar in 2026

These smaller innovators are quietly advancing promising therapies that could unlock their true potential.

SLN : 6.96 (-2.38%)
CRDL : 1.0500 (+9.22%)
TERN : 29.36 (+8.22%)
INO : 2.07 (+2.48%)
TARA : 5.58 (-18.78%)
ATRA : 14.33 (+0.92%)
Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)

Rapid Completion of Phase 2 Enrollment Reflects Ongoing Momentum for Divesiran as First-in-Class siRNA for PV Topline Results Anticipated in 3Q’26

SLN : 6.96 (-2.38%)
Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Silence Therapeutics (SLN – Research Report) and Cabaletta Bio (CABA – Research Report) with bullish...

CABA : 2.55 (-0.39%)
SLN : 6.96 (-2.38%)
Silence Therapeutics to Participate in September Investor Conferences

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will...

SLN : 6.96 (-2.38%)
Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

‒ Presented Updated SANRECO Phase 1 Data at EHA 2025 Further Supporting Potential for Divesiran as First-in-Class siRNA in PV ‒ SANRECO...

SLN : 6.96 (-2.38%)
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 6.96 (-2.38%)
Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 6.96 (-2.38%)
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 6.96 (-2.38%)

Business Summary

Silence Therapeutics plc focuses on the discovery, development and delivery of novel RNA therapeutics in hematology, cardiovascular and other rare and metabolic indications. The Company's product candidate consist SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease...

See More

Key Turning Points

3rd Resistance Point 8.00
2nd Resistance Point 7.71
1st Resistance Point 7.34
Last Price 6.96
1st Support Level 6.67
2nd Support Level 6.38
3rd Support Level 6.01

See More

52-Week High 8.88
Last Price 6.96
Fibonacci 61.8% 6.24
Fibonacci 50% 5.43
Fibonacci 38.2% 4.61
52-Week Low 1.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar